What is the P/E ratio of Mayinglong Pharmaceutical Group Co 2025?
The Mayinglong Pharmaceutical Group Co P/E ratio is 18.38.
Unlimited Access
Unlimited access to the most powerful analytical tools in finance.
20M+ Securities
Real-time Data
AI Insights
50Y History
8K+ News
Overview
Profile
Mayinglong Pharmaceutical Group Co Stock 600993.SSstock price, forecast, news, chart, split, dividend and analysis Mayinglong Pharmaceutical Group Co ariva, Mayinglong Pharmaceutical Group Co onvista, Mayinglong Pharmaceutical Group Co finanzen.net, Mayinglong Pharmaceutical Group Co aktienfinder, Mayinglong Pharmaceutical Group Co marketscreener, Mayinglong Pharmaceutical Group Co marketwatch, Mayinglong Pharmaceutical Group Co bloomberg, Mayinglong Pharmaceutical Group Co handelsblatt, Mayinglong Pharmaceutical Group Co wiwo, Mayinglong Pharmaceutical Group Co forum
600993.SS
CNE000001HN2
Price
Price
27.70
Today +/-
-0.03
Today %
-0.97 %
Ticker600993.SS
ISINCNE000001HN2
Mayinglong Pharmaceutical Group Co stock price
%
Weekly
Details
Price
ⓘOverview
The Quote Chart provides detailed and dynamic insights into the Mayinglong Pharmaceutical Group Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.
Intraday Feature
The intraday feature provides real-time data, allowing investors to view the Mayinglong Pharmaceutical Group Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.
Total Return and Relative Price Change
View the total return of the Mayinglong Pharmaceutical Group Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.
Interpretation and Investment
Utilize the comprehensive data presented in the Quote Chart to analyze Mayinglong Pharmaceutical Group Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.
Mayinglong Pharmaceutical Group Co Stock Price History
| Date | Mayinglong Pharmaceutical Group Co Price |
|---|---|
| 7/4/2025 | 27.70 undefined |
| 7/3/2025 | 27.97 undefined |
| 7/2/2025 | 27.81 undefined |
| 7/1/2025 | 28.11 undefined |
| 6/30/2025 | 28.28 undefined |
| 6/27/2025 | 28.63 undefined |
| 6/26/2025 | 28.44 undefined |
| 6/25/2025 | 28.31 undefined |
| 6/24/2025 | 28.12 undefined |
| 6/23/2025 | 28.04 undefined |
| 6/20/2025 | 28.15 undefined |
| 6/19/2025 | 28.80 undefined |
| 6/18/2025 | 28.02 undefined |
| 6/17/2025 | 28.07 undefined |
| 6/16/2025 | 28.41 undefined |
| 6/13/2025 | 28.65 undefined |
| 6/12/2025 | 28.76 undefined |
| 6/11/2025 | 29.14 undefined |
| 6/10/2025 | 29.36 undefined |
| 6/9/2025 | 29.39 undefined |
| 6/6/2025 | 29.40 undefined |
Mayinglong Pharmaceutical Group Co Revenue, EBIT, Net Income CNE000001HN2 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Mayinglong Pharmaceutical Group Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Mayinglong Pharmaceutical Group Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Mayinglong Pharmaceutical Group Co’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Mayinglong Pharmaceutical Group Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Mayinglong Pharmaceutical Group Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Mayinglong Pharmaceutical Group Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Mayinglong Pharmaceutical Group Co’s growth potential.
Mayinglong Pharmaceutical Group Co Revenue, EBIT and net profit per share
| Date | Mayinglong Pharmaceutical Group Co Revenue | Mayinglong Pharmaceutical Group Co EBIT | Mayinglong Pharmaceutical Group Co Net Income |
|---|---|---|---|
| 2027e | 5.61 B undefined | 964.55 M undefined | 862.02 M undefined |
| 2026e | 4.78 B undefined | 793.61 M undefined | 752.09 M undefined |
| 2025e | 4.25 B undefined | 686.55 M undefined | 649.78 M undefined |
| 2024 | 3.73 B undefined | 600.46 M undefined | 528.09 M undefined |
| 2023 | 3.14 B undefined | 399.74 M undefined | 443.25 M undefined |
| 2022 | 3.53 B undefined | 502.55 M undefined | 479 M undefined |
| 2021 | 3.39 B undefined | 465.03 M undefined | 464.59 M undefined |
| 2020 | 2.79 B undefined | 368.9 M undefined | 419.1 M undefined |
| 2019 | 2.71 B undefined | 387.6 M undefined | 360 M undefined |
| 2018 | 2.2 B undefined | 318.4 M undefined | 176.2 M undefined |
| 2017 | 1.75 B undefined | 274.1 M undefined | 320.1 M undefined |
| 2016 | 2.1 B undefined | 230 M undefined | 250.2 M undefined |
| 2015 | 1.78 B undefined | 204.1 M undefined | 223.3 M undefined |
| 2014 | 1.62 B undefined | 184.9 M undefined | 201.5 M undefined |
| 2013 | 1.6 B undefined | 182.5 M undefined | 186.3 M undefined |
| 2012 | 1.54 B undefined | 155.6 M undefined | 173.8 M undefined |
| 2011 | 1.42 B undefined | 169.6 M undefined | 137.7 M undefined |
| 2010 | 1.18 B undefined | 117.8 M undefined | 122.5 M undefined |
| 2009 | 1.02 B undefined | 113 M undefined | 180.1 M undefined |
| 2008 | 809.6 M undefined | 102.6 M undefined | 80.4 M undefined |
| 2007 | 548.6 M undefined | 50.8 M undefined | 133.4 M undefined |
| 2006 | 538.3 M undefined | 83.3 M undefined | 71.6 M undefined |
| 2005 | 411.8 M undefined | 73.6 M undefined | 60.1 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2005 | 411.8 M CNY | 73.6 M CNY | 60.1 M CNY |
| 2006 | 538.3 M CNY | 83.3 M CNY | 71.6 M CNY |
| 2007 | 548.6 M CNY | 50.8 M CNY | 133.4 M CNY |
| 2008 | 809.6 M CNY | 102.6 M CNY | 80.4 M CNY |
| 2009 | 1.02 B CNY | 113 M CNY | 180.1 M CNY |
| 2010 | 1.18 B CNY | 117.8 M CNY | 122.5 M CNY |
| 2011 | 1.42 B CNY | 169.6 M CNY | 137.7 M CNY |
| 2012 | 1.54 B CNY | 155.6 M CNY | 173.8 M CNY |
| 2013 | 1.6 B CNY | 182.5 M CNY | 186.3 M CNY |
| 2014 | 1.62 B CNY | 184.9 M CNY | 201.5 M CNY |
| 2015 | 1.78 B CNY | 204.1 M CNY | 223.3 M CNY |
| 2016 | 2.1 B CNY | 230 M CNY | 250.2 M CNY |
| 2017 | 1.75 B CNY | 274.1 M CNY | 320.1 M CNY |
| 2018 | 2.2 B CNY | 318.4 M CNY | 176.2 M CNY |
| 2019 | 2.71 B CNY | 387.6 M CNY | 360 M CNY |
| 2020 | 2.79 B CNY | 368.9 M CNY | 419.1 M CNY |
| 2021 | 3.39 B CNY | 465.03 M CNY | 464.59 M CNY |
| 2022 | 3.53 B CNY | 502.55 M CNY | 479 M CNY |
| 2023 | 3.14 B CNY | 399.74 M CNY | 443.25 M CNY |
| 2024 | 3.73 B CNY | 600.46 M CNY | 528.09 M CNY |
| 2025e | 4.25 B CNY | 686.55 M CNY | 649.78 M CNY |
| 2026e | 4.78 B CNY | 793.61 M CNY | 752.09 M CNY |
| 2027e | 5.61 B CNY | 964.55 M CNY | 862.02 M CNY |
Mayinglong Pharmaceutical Group Co Income Statement, Balance Sheet, Cash Flow Statement
Simple
Expanded
Income Statement
Balance Sheet
Cashflow
| REVENUE (B) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (B) |
| NET INCOME (M) |
| NET INCOME GROWTH (%) |
| DIVIDEND ()DIV. () |
| DIVIDEND GROWTH (%)DIV. GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.2 | 0.25 | 0.33 | 0.37 | 0.41 | 0.54 | 0.55 | 0.81 | 1.02 | 1.18 | 1.42 | 1.54 | 1.6 | 1.62 | 1.78 | 2.1 | 1.75 | 2.2 | 2.71 | 2.79 | 3.39 | 3.53 | 3.14 | 3.73 | 4.25 | 4.78 | 5.61 |
| - | 21.57 | 31.05 | 14.15 | 10.78 | 30.90 | 1.86 | 47.63 | 26.33 | 15.26 | 20.12 | 8.98 | 3.89 | 1.12 | 10.06 | 17.89 | -16.75 | 25.54 | 23.12 | 3.18 | 21.28 | 4.34 | -11.21 | 18.88 | 13.92 | 12.53 | 17.30 |
| 65.20 | 64.11 | 57.85 | 55.53 | 56.69 | 47.03 | 41.97 | 37.82 | 36.89 | 36.76 | 38.37 | 40.53 | 42.70 | 41.73 | 39.37 | 36.11 | 50.06 | 45.06 | 40.92 | 40.42 | 40.35 | 42.30 | 41.68 | 46.41 | 40.73 | 36.20 | 30.86 |
| 0.13 | 0.16 | 0.19 | 0.21 | 0.23 | 0.25 | 0.23 | 0.31 | 0.38 | 0.43 | 0.54 | 0.63 | 0.68 | 0.68 | 0.7 | 0.76 | 0.88 | 0.99 | 1.11 | 1.13 | 1.37 | 1.49 | 1.31 | 1.73 | 0 | 0 | 0 |
| 27 | 32 | 39 | 52 | 60 | 71 | 133 | 80 | 180 | 122 | 137 | 173 | 186 | 201 | 223 | 250 | 320 | 176 | 360 | 419 | 464 | 479 | 443 | 528 | 649 | 752 | 862 |
| - | 18.52 | 21.88 | 33.33 | 15.38 | 18.33 | 87.32 | -39.85 | 125.00 | -32.22 | 12.30 | 26.28 | 7.51 | 8.06 | 10.95 | 12.11 | 28.00 | -45.00 | 104.55 | 16.39 | 10.74 | 3.23 | -7.52 | 19.19 | 22.92 | 15.87 | 14.63 |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 284.7 | 279.4 | 279.4 | 431.1 | 431.1 | 431.1 | 431.1 | 431.1 | 431.1 | 431.1 | 431.1 | 431.1 | 431.1 | 431.1 | 431.1 | 431.1 | 431.1 | 431.1 | 431.1 | 431.1 | 431.05 | 431.05 | 431.05 | 431.05 | 0 | 0 | 0 |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Details
Keystats
ⓘRevenue and Growth
The Mayinglong Pharmaceutical Group Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.
Gross Margin
The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.
EBIT and EBIT Margin
EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.
Income and Growth
Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.
Shares Outstanding
Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.
Interpreting Year to Year Comparison
Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.
Expectations and Predictions
Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Mayinglong Pharmaceutical Group Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.
Mayinglong Pharmaceutical Group Co stock margins CNE000001HN2 ·
The Mayinglong Pharmaceutical Group Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Mayinglong Pharmaceutical Group Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Mayinglong Pharmaceutical Group Co.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Mayinglong Pharmaceutical Group Co's sales revenue. A higher gross margin percentage indicates that the Mayinglong Pharmaceutical Group Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Mayinglong Pharmaceutical Group Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Mayinglong Pharmaceutical Group Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Mayinglong Pharmaceutical Group Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Mayinglong Pharmaceutical Group Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Mayinglong Pharmaceutical Group Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Mayinglong Pharmaceutical Group Co Margin History
| Mayinglong Pharmaceutical Group Co Gross margin | Mayinglong Pharmaceutical Group Co Profit margin | Mayinglong Pharmaceutical Group Co EBIT margin | Mayinglong Pharmaceutical Group Co Profit margin |
|---|---|---|---|
| 2027e | 46.43 % | 17.21 % | 15.38 % |
| 2026e | 46.43 % | 16.61 % | 15.74 % |
| 2025e | 46.43 % | 16.17 % | 15.3 % |
| 2024 | 46.43 % | 16.11 % | 14.17 % |
| 2023 | 41.68 % | 12.74 % | 14.13 % |
| 2022 | 42.3 % | 14.23 % | 13.56 % |
| 2021 | 40.36 % | 13.74 % | 13.72 % |
| 2020 | 40.42 % | 13.21 % | 15.01 % |
| 2019 | 40.95 % | 14.33 % | 13.31 % |
| 2018 | 45.09 % | 14.49 % | 8.02 % |
| 2017 | 50.06 % | 15.66 % | 18.29 % |
| 2016 | 36.11 % | 10.94 % | 11.9 % |
| 2015 | 39.41 % | 11.44 % | 12.52 % |
| 2014 | 41.76 % | 11.41 % | 12.43 % |
| 2013 | 42.71 % | 11.39 % | 11.63 % |
| 2012 | 40.54 % | 10.09 % | 11.27 % |
| 2011 | 38.39 % | 11.98 % | 9.73 % |
| 2010 | 36.8 % | 10 % | 10.39 % |
| 2009 | 36.97 % | 11.06 % | 17.62 % |
| 2008 | 37.9 % | 12.67 % | 9.93 % |
| 2007 | 42.03 % | 9.26 % | 24.32 % |
| 2006 | 47.13 % | 15.47 % | 13.3 % |
| 2005 | 56.61 % | 17.87 % | 14.59 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2005 | 56.61 % | 17.87 % | 14.59 % |
| 2006 | 47.13 % | 15.47 % | 13.3 % |
| 2007 | 42.03 % | 9.26 % | 24.32 % |
| 2008 | 37.9 % | 12.67 % | 9.93 % |
| 2009 | 36.97 % | 11.06 % | 17.62 % |
| 2010 | 36.8 % | 10 % | 10.39 % |
| 2011 | 38.39 % | 11.98 % | 9.73 % |
| 2012 | 40.54 % | 10.09 % | 11.27 % |
| 2013 | 42.71 % | 11.39 % | 11.63 % |
| 2014 | 41.76 % | 11.41 % | 12.43 % |
| 2015 | 39.41 % | 11.44 % | 12.52 % |
| 2016 | 36.11 % | 10.94 % | 11.9 % |
| 2017 | 50.06 % | 15.66 % | 18.29 % |
| 2018 | 45.09 % | 14.49 % | 8.02 % |
| 2019 | 40.95 % | 14.33 % | 13.31 % |
| 2020 | 40.42 % | 13.21 % | 15.01 % |
| 2021 | 40.36 % | 13.74 % | 13.72 % |
| 2022 | 42.3 % | 14.23 % | 13.56 % |
| 2023 | 41.68 % | 12.74 % | 14.13 % |
| 2024 | 46.43 % | 16.11 % | 14.17 % |
| 2025e | 46.43 % | 16.17 % | 15.3 % |
| 2026e | 46.43 % | 16.61 % | 15.74 % |
| 2027e | 46.43 % | 17.21 % | 15.38 % |
Mayinglong Pharmaceutical Group Co Stock Sales Revenue, EBIT, Earnings per Share CNE000001HN2 ·
The Mayinglong Pharmaceutical Group Co earnings per share therefore indicates how much revenue Mayinglong Pharmaceutical Group Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
3 years
5 years
10 years
25 Years
Max
Sales per Share
EBIT per share
Earnings per Share
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Mayinglong Pharmaceutical Group Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Mayinglong Pharmaceutical Group Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Mayinglong Pharmaceutical Group Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Mayinglong Pharmaceutical Group Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Mayinglong Pharmaceutical Group Co Revenue, EBIT and net profit per share
| Date | Mayinglong Pharmaceutical Group Co Sales per Share | Mayinglong Pharmaceutical Group Co EBIT per share | Mayinglong Pharmaceutical Group Co Earnings per Share |
|---|---|---|---|
| 2027e | 13.01 undefined | 0 undefined | 2 undefined |
| 2026e | 11.09 undefined | 0 undefined | 1.74 undefined |
| 2025e | 9.85 undefined | 0 undefined | 1.51 undefined |
| 2024 | 8.65 undefined | 1.39 undefined | 1.23 undefined |
| 2023 | 7.28 undefined | 0.93 undefined | 1.03 undefined |
| 2022 | 8.19 undefined | 1.17 undefined | 1.11 undefined |
| 2021 | 7.85 undefined | 1.08 undefined | 1.08 undefined |
| 2020 | 6.48 undefined | 0.86 undefined | 0.97 undefined |
| 2019 | 6.28 undefined | 0.9 undefined | 0.84 undefined |
| 2018 | 5.1 undefined | 0.74 undefined | 0.41 undefined |
| 2017 | 4.06 undefined | 0.64 undefined | 0.74 undefined |
| 2016 | 4.88 undefined | 0.53 undefined | 0.58 undefined |
| 2015 | 4.14 undefined | 0.47 undefined | 0.52 undefined |
| 2014 | 3.76 undefined | 0.43 undefined | 0.47 undefined |
| 2013 | 3.72 undefined | 0.42 undefined | 0.43 undefined |
| 2012 | 3.58 undefined | 0.36 undefined | 0.4 undefined |
| 2011 | 3.28 undefined | 0.39 undefined | 0.32 undefined |
| 2010 | 2.73 undefined | 0.27 undefined | 0.28 undefined |
| 2009 | 2.37 undefined | 0.26 undefined | 0.42 undefined |
| 2008 | 1.88 undefined | 0.24 undefined | 0.19 undefined |
| 2007 | 1.27 undefined | 0.12 undefined | 0.31 undefined |
| 2006 | 1.25 undefined | 0.19 undefined | 0.17 undefined |
| 2005 | 0.96 undefined | 0.17 undefined | 0.14 undefined |
| Sales per Share | EBIT per share | Earnings per Share | |
|---|---|---|---|
| 2005 | 0.96 CNY | 0.17 CNY | 0.14 CNY |
| 2006 | 1.25 CNY | 0.19 CNY | 0.17 CNY |
| 2007 | 1.27 CNY | 0.12 CNY | 0.31 CNY |
| 2008 | 1.88 CNY | 0.24 CNY | 0.19 CNY |
| 2009 | 2.37 CNY | 0.26 CNY | 0.42 CNY |
| 2010 | 2.73 CNY | 0.27 CNY | 0.28 CNY |
| 2011 | 3.28 CNY | 0.39 CNY | 0.32 CNY |
| 2012 | 3.58 CNY | 0.36 CNY | 0.4 CNY |
| 2013 | 3.72 CNY | 0.42 CNY | 0.43 CNY |
| 2014 | 3.76 CNY | 0.43 CNY | 0.47 CNY |
| 2015 | 4.14 CNY | 0.47 CNY | 0.52 CNY |
| 2016 | 4.88 CNY | 0.53 CNY | 0.58 CNY |
| 2017 | 4.06 CNY | 0.64 CNY | 0.74 CNY |
| 2018 | 5.1 CNY | 0.74 CNY | 0.41 CNY |
| 2019 | 6.28 CNY | 0.9 CNY | 0.84 CNY |
| 2020 | 6.48 CNY | 0.86 CNY | 0.97 CNY |
| 2021 | 7.85 CNY | 1.08 CNY | 1.08 CNY |
| 2022 | 8.19 CNY | 1.17 CNY | 1.11 CNY |
| 2023 | 7.28 CNY | 0.93 CNY | 1.03 CNY |
| 2024 | 8.65 CNY | 1.39 CNY | 1.23 CNY |
| 2025e | 9.85 CNY | 0 CNY | 1.51 CNY |
| 2026e | 11.09 CNY | 0 CNY | 1.74 CNY |
| 2027e | 13.01 CNY | 0 CNY | 2 CNY |
Mayinglong Pharmaceutical Group Co business model
Mayinglong Pharmaceutical Group Co is one of the most popular companies on Eulerpool.com.
Mayinglong Pharmaceutical Group Co Eulerpool Fair Value
Details
Fair Value
ⓘUnderstanding Fair Value
The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.
Income-Based Fair Value
This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.
Example 2022
Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)
Revenue-Based Fair Value
It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.
Example 2022
Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)
Dividend-Based Fair Value
This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.
Example 2022
Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)
Expectations and Forecasts
Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.
Comparative Analysis
Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.
Mayinglong Pharmaceutical Group Co historical P/E ratio, EBIT multiple, and P/S ratio
Mayinglong Pharmaceutical Group Co shares outstanding CNE000001HN2 ·
The number of shares was Mayinglong Pharmaceutical Group Co in 2024 — This indicates how many shares 431.054 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Mayinglong Pharmaceutical Group Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Mayinglong Pharmaceutical Group Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Mayinglong Pharmaceutical Group Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Mayinglong Pharmaceutical Group Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2005 | 431.1 M Aktien |
| 2006 | 431.1 M Aktien |
| 2007 | 431.1 M Aktien |
| 2008 | 431.1 M Aktien |
| 2009 | 431.1 M Aktien |
| 2010 | 431.1 M Aktien |
| 2011 | 431.1 M Aktien |
| 2012 | 431.1 M Aktien |
| 2013 | 431.1 M Aktien |
| 2014 | 431.1 M Aktien |
| 2015 | 431.1 M Aktien |
| 2016 | 431.1 M Aktien |
| 2017 | 431.1 M Aktien |
| 2018 | 431.1 M Aktien |
| 2019 | 431.1 M Aktien |
| 2020 | 431.1 M Aktien |
| 2021 | 431.05 M Aktien |
| 2022 | 431.05 M Aktien |
| 2023 | 431.05 M Aktien |
| 2024 | 431.05 M Aktien |
| 2025e | 431.05 M Aktien |
| 2026e | 431.05 M Aktien |
| 2027e | 431.05 M Aktien |
Mayinglong Pharmaceutical Group Co stock splits
In Mayinglong Pharmaceutical Group Co's history, there have been no stock splits.
Mayinglong Pharmaceutical Group Co dividend history and estimates CNE000001HN2 ·
In 2024, Mayinglong Pharmaceutical Group Co paid a dividend amounting to 0.4 CNY. Dividend means that Mayinglong Pharmaceutical Group Co distributes a portion of its profits to its owners.
3 years
5 years
10 years
25 Years
Max
Dividend
Dividend (Estimate)
Details
Dividend
ⓘDividend Overview
The dividend per year chart for Mayinglong Pharmaceutical Group Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.
Interpretation and Use
A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Mayinglong Pharmaceutical Group Co’s potential for long-term investment and income generation through dividends.
Investment Strategy
Incorporate the dividend data in evaluating Mayinglong Pharmaceutical Group Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.
Mayinglong Pharmaceutical Group Co Dividend History
| Date | Mayinglong Pharmaceutical Group Co Dividend |
|---|---|
| 2027e | 0.44 undefined |
| 2026e | 0.44 undefined |
| 2025e | 0.44 undefined |
| 2024 | 0.4 undefined |
| 2023 | 0.35 undefined |
| 2022 | 0.35 undefined |
| 2021 | 0.3 undefined |
| 2020 | 0.26 undefined |
| 2019 | 0.15 undefined |
| 2018 | 0.23 undefined |
| 2017 | 0.2 undefined |
| 2016 | 0.2 undefined |
| 2015 | 0.03 undefined |
| 2014 | 0.13 undefined |
| 2013 | 0.12 undefined |
| 2012 | 0.08 undefined |
| 2011 | 0.02 undefined |
| 2010 | 0.23 undefined |
| 2009 | 0.04 undefined |
| 2008 | 0.09 undefined |
| 2007 | 0.06 undefined |
| 2006 | 0.28 undefined |
| 2005 | 0.1 undefined |
| Dividend | Dividend (Estimate) | |
|---|---|---|
| 2005 | 0.1 CNY | 0 CNY |
| 2006 | 0.28 CNY | 0 CNY |
| 2007 | 0.06 CNY | 0 CNY |
| 2008 | 0.09 CNY | 0 CNY |
| 2009 | 0.04 CNY | 0 CNY |
| 2010 | 0.23 CNY | 0 CNY |
| 2011 | 0.02 CNY | 0 CNY |
| 2012 | 0.08 CNY | 0 CNY |
| 2013 | 0.12 CNY | 0 CNY |
| 2014 | 0.13 CNY | 0 CNY |
| 2015 | 0.03 CNY | 0 CNY |
| 2016 | 0.2 CNY | 0 CNY |
| 2017 | 0.2 CNY | 0 CNY |
| 2018 | 0.23 CNY | 0 CNY |
| 2019 | 0.15 CNY | 0 CNY |
| 2020 | 0.26 CNY | 0 CNY |
| 2021 | 0.3 CNY | 0 CNY |
| 2022 | 0.35 CNY | 0 CNY |
| 2023 | 0.35 CNY | 0 CNY |
| 2024 | 0.4 CNY | 0 CNY |
| 2025e | 0 CNY | 0.44 CNY |
| 2026e | 0 CNY | 0.44 CNY |
| 2027e | 0 CNY | 0.44 CNY |
Mayinglong Pharmaceutical Group Co dividend payout ratio CNE000001HN2 ·
In 2024, Mayinglong Pharmaceutical Group Co had a payout ratio of 29.35%. The payout ratio indicates the percentage of the company's profits that Mayinglong Pharmaceutical Group Co distributes as dividends.
3 years
5 years
10 years
25 Years
Max
Payout ratio
Details
Payout ratio
ⓘWhat is Yearly Payout Ratio?
The yearly payout ratio for Mayinglong Pharmaceutical Group Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.
How to Interpret the Data
A lower payout ratio for Mayinglong Pharmaceutical Group Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.
Using the Data for Investments
Evaluate Mayinglong Pharmaceutical Group Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.
Mayinglong Pharmaceutical Group Co Payout Ratio History
| Date | Mayinglong Pharmaceutical Group Co Payout ratio |
|---|---|
| 2027e | 29.5 % |
| 2026e | 29.3 % |
| 2025e | 29.85 % |
| 2024 | 29.35 % |
| 2023 | 28.71 % |
| 2022 | 31.5 % |
| 2021 | 27.83 % |
| 2020 | 26.8 % |
| 2019 | 17.86 % |
| 2018 | 56.1 % |
| 2017 | 27.03 % |
| 2016 | 34.48 % |
| 2015 | 5.92 % |
| 2014 | 27.83 % |
| 2013 | 28.63 % |
| 2012 | 21.15 % |
| 2011 | 6 % |
| 2010 | 82.43 % |
| 2009 | 10.17 % |
| 2008 | 45 % |
| 2007 | 18.39 % |
| 2006 | 166.59 % |
| 2005 | 67.86 % |
| Payout ratio | |
|---|---|
| 2005 | 67.86 % |
| 2006 | 166.59 % |
| 2007 | 18.39 % |
| 2008 | 45 % |
| 2009 | 10.17 % |
| 2010 | 82.43 % |
| 2011 | 6 % |
| 2012 | 21.15 % |
| 2013 | 28.63 % |
| 2014 | 27.83 % |
| 2015 | 5.92 % |
| 2016 | 34.48 % |
| 2017 | 27.03 % |
| 2018 | 56.1 % |
| 2019 | 17.86 % |
| 2020 | 26.8 % |
| 2021 | 27.83 % |
| 2022 | 31.5 % |
| 2023 | 28.71 % |
| 2024 | 29.35 % |
| 2025e | 29.85 % |
| 2026e | 29.3 % |
| 2027e | 29.5 % |
Unfortunately, there are currently no price targets and forecasts available for Mayinglong Pharmaceutical Group Co.
Mayinglong Pharmaceutical Group Co latest earnings and earnings surprises
| Date | EPS Estimate | EPS Actual | Quarterly report |
|---|---|---|---|
| 3/31/2019 | 0.28 | 0.31 (9.36 %) | 2019 Q1 |
| 12/31/2018 | 0.58 | 0.13 (-77.86 %) | 2018 Q4 |
| 9/30/2018 | 0.04 | 0.04 (11.98 %) | 2018 Q3 |
| 6/30/2018 | 0.07 | 0.08 (21.77 %) | 2018 Q2 |
| 3/31/2018 | 0.26 | 0.16 (-38.37 %) | 2018 Q1 |
| 12/31/2017 | 0.11 | 0.2 (81.06 %) | 2017 Q4 |
| 9/30/2017 | 0.1 | 0.15 (48.51 %) | 2017 Q3 |
| 6/30/2017 | 0.2 | 0.2 (2.09 %) | 2017 Q2 |
| 3/31/2017 | 0.25 | 0.2 (-21.1 %) | 2017 Q1 |
| 12/31/2016 | 0.1 | 0.1 (-2.25 %) | 2016 Q4 |
1
2
3
Mayinglong Pharmaceutical Group Co shareholders
% | Name | Stocks | Change | Date |
|---|---|---|---|---|
| 29.26857 % | China Baoan Group Co Ltd | 126,163,313 | 0 | 9/30/2024 |
| 5.20810 % | Wuhan State-owned Capital Investment Operation Group Co., Ltd. | 22,449,723 | 0 | 9/30/2024 |
| 4.76567 % | Bank of Communications Schroder Fund Management Co., Ltd. | 20,542,598 | 1,422,516 | 9/30/2024 |
| 2.81069 % | Zhong Ou Asset Management Co., Ltd. | 12,115,593 | 8,126,436 | 6/30/2024 |
| 1.66019 % | UBS Asset Management (Hong Kong) Limited | 7,156,300 | 556,500 | 11/30/2024 |
| 1.65453 % | Beijing Yuanfeng Private Equity Fund Management Partnership (L.P.) | 7,131,912 | 2,524,500 | 9/30/2024 |
| 1.62244 % | Bank of China Investment Management Co., Ltd. | 6,993,600 | 4,716,500 | 6/30/2024 |
| 1.61649 % | China Universal Asset Management Co., Ltd. | 6,967,935 | 5,267,630 | 6/30/2024 |
| 1.56723 % | Harvest Fund Management Co., Ltd. | 6,755,623 | 359,600 | 9/30/2024 |
| 1.34480 % | China Southern Asset Management Co. Ltd. | 5,796,816 | 706,100 | 9/30/2024 |
1
2
3
4
5
...
10
Mayinglong Pharmaceutical Group Co Executives and Management Board
Mr. Youzhang Xia
(35)Mayinglong Pharmaceutical Group Co General Manager, Director (since 2010)
Compensation 1.06 M
Mr. Zhiqi Song
(47)Mayinglong Pharmaceutical Group Co Deputy General Manager
Compensation 968,000
Mr. Guangxiang Su
(59)Mayinglong Pharmaceutical Group Co Vice Chairman of the Board (since 2005)
Compensation 886,000
Mr. Zhengjun Tian
(54)Mayinglong Pharmaceutical Group Co Deputy General Manager (since 2019)
Compensation 826,000
Mr. Daonian Zhou
(40)Mayinglong Pharmaceutical Group Co Assistant General Manager
Compensation 800,000
1
2
3
4
Mayinglong Pharmaceutical Group Co Supply Chain
| Name | Relationship | Two-week correlation | One-month correlation | Three-Month Correlation | Six-Month Correlation | One Year Correlation | Two-Year Correlation |
|---|---|---|---|---|---|---|---|
| SupplierCustomer | -0,17 | 0,71 | 0,77 | 0,68 | 0,75 | 0,73 |
1
Most common questions regarding Mayinglong Pharmaceutical Group Co
What is the P/S ratio of Mayinglong Pharmaceutical Group Co 2025?
The Mayinglong Pharmaceutical Group Co P/S ratio is 2.81.
What is the Quality Investing of Mayinglong Pharmaceutical Group Co?
The Quality Investing for Mayinglong Pharmaceutical Group Co is 7/10.
What is the revenue of Mayinglong Pharmaceutical Group Co 2025?
The expected Mayinglong Pharmaceutical Group Co revenue is 4.25 B CNY.
How high is the profit of Mayinglong Pharmaceutical Group Co 2025?
The expected Mayinglong Pharmaceutical Group Co profit is 649.78 M CNY.
What is the business model of Mayinglong Pharmaceutical Group Co
No history available for Mayinglong Pharmaceutical Group Co.
What is the Mayinglong Pharmaceutical Group Co dividend?
Mayinglong Pharmaceutical Group Co pays a dividend of 0.35 CNY distributed over payouts per year.
How often does Mayinglong Pharmaceutical Group Co pay dividends?
The dividend cannot currently be calculated for Mayinglong Pharmaceutical Group Co or the company does not pay out a dividend.
What is the Mayinglong Pharmaceutical Group Co ISIN?
The ISIN of Mayinglong Pharmaceutical Group Co is CNE000001HN2.
What is the Mayinglong Pharmaceutical Group Co ticker?
The ticker of Mayinglong Pharmaceutical Group Co is 600993.SS.
How much dividend does Mayinglong Pharmaceutical Group Co pay?
Over the past 12 months, Mayinglong Pharmaceutical Group Co paid a dividend of 0.4 CNY . This corresponds to a dividend yield of about 1.44 %. For the coming 12 months, Mayinglong Pharmaceutical Group Co is expected to pay a dividend of 0.44 CNY.
What is the dividend yield of Mayinglong Pharmaceutical Group Co?
The current dividend yield of Mayinglong Pharmaceutical Group Co is 1.44 %.
When does Mayinglong Pharmaceutical Group Co pay dividends?
Mayinglong Pharmaceutical Group Co pays a quarterly dividend. This is distributed in the months of August, August, August, August.
How secure is the dividend of Mayinglong Pharmaceutical Group Co?
Mayinglong Pharmaceutical Group Co paid dividends every year for the past 23 years.
What is the dividend of Mayinglong Pharmaceutical Group Co?
For the upcoming 12 months, dividends amounting to 0.44 CNY are expected. This corresponds to a dividend yield of 1.58 %.
In which sector is Mayinglong Pharmaceutical Group Co located?
Mayinglong Pharmaceutical Group Co is assigned to the 'Health' sector.
Wann musste ich die Aktien von Mayinglong Pharmaceutical Group Co kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Mayinglong Pharmaceutical Group Co from 7/26/2024 amounting to 0.4 CNY, you needed to have the stock in your portfolio before the ex-date on 7/26/2024.
When did Mayinglong Pharmaceutical Group Co pay the last dividend?
The last dividend was paid out on 7/26/2024.
What was the dividend of Mayinglong Pharmaceutical Group Co in the year 2024?
In the year 2024, Mayinglong Pharmaceutical Group Co distributed 0.35 CNY as dividends.
In which currency does Mayinglong Pharmaceutical Group Co pay out the dividend?
The dividends of Mayinglong Pharmaceutical Group Co are distributed in CNY.
Mayinglong Pharmaceutical Group Co stock
Sector
Health
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
People's Republic of China 🇨🇳
Currency
CNY
Initial public offering
May 17, 2004
ISIN
CNE000001HN2
GOSIN
Global Open Securities Identification Number
Cusip
Y97116100
Market capitalization
Quality Investing
7 / 10Details
PEG
0
P/E ratio
Forward P/E ratio
0
P/S ratio
Forward P/S ratio
0
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
8.48 %
Dividend
Dividend yield
0 %
Dividend growth Ø5Y
9 %
Dividend payments per year
Dividend paid since
20 years
Dividend not reduced since
4 years
Dividend increased since
4 years
Dividend withholding tax
25.83 %
Mayinglong Pharmaceutical Group Co Peer Group
Mayinglong Pharmaceutical Group Co Eulerpool News
Mayinglong Pharmaceutical Group Co News
Mayinglong Pharmaceutical Group Co Ticker
| Stock Exchange | Mayinglong Pharmaceutical Group Co Ticker |
|---|---|
| SHH | 600993.SS |
Mayinglong Pharmaceutical Group Co FIGI
| Mayinglong Pharmaceutical Group Co Ticker | Mayinglong Pharmaceutical Group Co FIGI |
|---|---|
| 600993:CH | BBG000LJTC51 |
| 600993:CG | BBG000LJTCH8 |
| 600993:C1 | BBG00709J7C5 |
All fundamentals about Mayinglong Pharmaceutical Group Co
Our stock analysis for Mayinglong Pharmaceutical Group Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mayinglong Pharmaceutical Group Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Mayinglong Pharmaceutical Group Co Revenue
- Mayinglong Pharmaceutical Group Co Net Income
- Mayinglong Pharmaceutical Group Co P/E
- Mayinglong Pharmaceutical Group Co P/S
- Mayinglong Pharmaceutical Group Co EBIT
- Mayinglong Pharmaceutical Group Co Dividend
- Mayinglong Pharmaceutical Group Co Stocks
- Mayinglong Pharmaceutical Group Co Market capitalization
- Mayinglong Pharmaceutical Group Co Debt
- Mayinglong Pharmaceutical Group Co Liabilities
- Mayinglong Pharmaceutical Group Co Equity
- Mayinglong Pharmaceutical Group Co AAQS
- Mayinglong Pharmaceutical Group Co Employees
- Mayinglong Pharmaceutical Group Co ROE
- Mayinglong Pharmaceutical Group Co ROA
- Mayinglong Pharmaceutical Group Co ROCE